Characterization of Patients with Duchenne Muscular Dystrophy across Previously Developed Health States

Author(s)

Muntoni F1, Goemans N2, Posner N3, Signorovitch J4, Johnson M4, Gomez-Lievano A4, He C4, Dorling P5, Beaverson K6, Alvir J7, Mahn M3, Ward SJ8, McDonald C9, Vandenborne K10, Mercuri E11
1University College London, London, UK, 2University Hospitals Leuven, Leuven, Belgium, 3Pfizer Inc., New York, NY, USA, 4Analysis Group, Inc., Boston, MA, USA, 5Chiesi USA, Cos Cob, CT, USA, 6Pfizer, New York, NJ, USA, 7Pfizer, Collegeville, PA, USA, 8Collaborative Trajectory Analysis Project (cTAP), Cambridge, MA, USA, 9University of California, Sacramento, CA, USA, 10University of Florida, Gainesville, FL, USA, 11Fondazione Policlinico Universitario "Agostino Gemelli", Roma, Italy

OBJECTIVES: The natural history of disease progression in Duchenne muscular dystrophy (DMD) has been categorized into eight health states based on the input from clinicians, patients, and caregivers by Project HERCULES. The current study uses natural history data to further characterize patients with DMD by health state.

METHODS: Patients from nine data sources (five clinical trial placebo arms, one real-world data and three natural history data) were categorized into eight health states based on the model reported by Project HERCULES: two ambulatory states, one transfer state, and five non-ambulatory states. State definitions were modified and verified, with clinical input, to account for data availability. Demographic and functional measures were characterized within each health state.

RESULTS: The study included 1,175 patients across 5,296 visits (4,989 ambulatory and 307 non-ambulatory visits). Patients were predominantly white and not Hispanic or Latino. Within each health state, substantial variation was observed for each functional measure assessed, but on average, patients were older and exhibited worse ambulatory function, pulmonary capacity, upper limb function and cardiac function for each subsequent health state. North Star Ambulatory Assessment (NSAA) total score was 23.7 (IQR 20-30) for early ambulatory patients, 12.7 (IQR 9-16) for the late ambulatory, and 3.8 (IQR 2.8-5) for transfer patients. Spirometry as measured by FVC%-predicted was 93.0±0.7 for ambulatory and transfer patients and was 77.2±1.7, 69.3±4.6, 42.3±1.2, 39.2±1.3, and 20.6±1.6 for the five respective non-ambulatory health states. Until the last health state (requiring full ventilation), over approximately 80% of patients were on steroids (either deflazacort or prednisone), with approximately 70% of patient visits using them daily.

CONCLUSIONS: Health states proposed for DMD disease progression showed concordantly worsened function for later health states across different domains, including ambulatory, pulmonary, upper-limb and cardiac function. These findings further characterize health states and their interpretation in economic modeling and decision-making.

Conference/Value in Health Info

2023-05, ISPOR 2023, Boston, MA, USA

Value in Health, Volume 26, Issue 6, S2 (June 2023)

Code

PCR28

Topic

Patient-Centered Research

Topic Subcategory

Health State Utilities, Instrument Development, Validation, & Translation

Disease

No Additional Disease & Conditions/Specialized Treatment Areas

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×